Expression of a panel of cytoskeletal proteins including the non-muscle myosin II (MYH9) was previously reported by our lab to be significantly up-regulated in the drug-resistant mesenchymal neuroblastoma cell line, SK-N-ASCis24, and shown to be central to ROCK1-independent cytoskeletal restructuring and increased migratory potential following cisplatin selection (Piskareva et al., 2015). Here, MYH9 is linked to neuroblastoma.